

Advanced breast cancer Committee meeting

Date: 24.03.2017

Location: Manchester

Minutes: Final



Committee members present:		
Tessa Lewis (Chair)		(Present for notes 1 – 6)
Alison Eastwood		(Present for notes 1 – 6)
Sarah Fishburn		(Present for notes 1 – 6)
Imran Jawaid		(Present for notes 1 – 6)
Catriona McDaid		(Present for notes 1 – 6)
Victoria Hetherington		(Present for notes 1 – 6)
Rosemary Buck (Topic adviser)		(Present for notes 1 – 6)
Maureen Daley (Topic adviser)		(Present for notes 1 – 6)
John Graham (Topic adviser)		(Present for notes 4 – 7)
Miles Howe (Topic adviser)		(Present for notes 1 – 6)
Karen McAdam (Topic adviser)		(Present for notes 4 – 5)

In attendance:		
Omnia Abdulrazeg	NICE Technical analyst	(Present for notes 1 – 6)
Ben Johnson	NICE Senior health economist	(Present for notes 1 – 6)
Caroline Kier	NICE Guideline commissioning manager	(Present for notes 1 – 6)
Susannah Moon	NICE Programme manager	(Present for notes 1 – 6)
Joshua Pink	NICE Technical advisor	(Present for notes 1 – 6)

Observers:	
David Tyldesley (NICE)	(Present for notes 1 – 6)
Yolanda Martinez (NICE)	(Present for notes 1 – 6)

Apologies:	
John Cape	Committee member
Gail Fortes-Mayer	Committee member
Nick Screaton	Committee member
Sophie Wilne	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the second meeting on advanced breast cancer. The Committee members and attendees introduced themselves.

The Chair welcomed the members of the public to the meeting. The members of the public had been briefed already, both verbally and in writing by the NICE team, and the Chair reminded them of the protocol for members of the public, whose role is to observe (they should not speak or ask questions). No filming or recording of the meeting is permitted. The Chair reminded all present that the Committee is independent and advisory, that its decisions and recommendations to NICE do not represent final NICE guidance, and that they may be changed as a result of public consultation.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: a recap of the clinical evidence for the review question; consideration of the economic evidence; drafting recommendations and considering equalities issues.

Introductions

The Chair welcomed new topic expert Miles Howe and thanked him for joining the Committee.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was: *the clinical and cost effectiveness of retesting receptor status in patients with advanced breast cancer.*

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
------	-------------------------	---	------------------	----------------

Karen McAdam	Consultant Medical Oncologist, Peterborough City Hospital	Ribociclib Advisory Board - Novartis November 2016 – travel and honorarium fee – first line metastatic HER2 negative and ER positive. Declared 24/03/17	Personal Financial Specific	Declare and leave for recommendation making
Karen McAdam	Consultant Medical Oncologist, Peterborough City Hospital	Roche Speaker Payment Fee November 2016 for breast cancer study day on neoadjuvant chemotherapy and trastuzumab. Declared 24/03/17	Personal Financial Specific	Declare and leave for recommendation making

The Chair and a senior member of the Developer’s team noted that the following members would not participate in a part of the meeting:

- Karen McAdam is unable to participate in section 5

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations

The Chair introduced Omnia Abdulrazeg, technical analyst, who gave a presentation on the clinical evidence and current recommendations relating to the review question.

Omnia took questions from the group.

The Chair introduced Ben Johnson, senior health economist, who gave a presentation on the economic evidence relating to the review question.

Ben took questions from the group.

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Omnia and Ben for their presentations.

The Committee thanked Omnia and Ben for their presentations and contribution to the development of the guideline.

5. Drafting recommendations

The Committee discussed the evidence presented and drafted recommendations.

6. Other issues

The Committee considered the following equalities issues:

- | |
|--|
| <ul style="list-style-type: none">• Age• Disability• Pregnancy and maternity |
|--|

Any other business

There were no further items to discuss. The Chair thanked the Committee and NICE team and closed the meeting.

Date of next meeting: 23/06/2017

Location of next meeting: Manchester